Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Tasigna

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 4,036Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 11Tasigna

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Tasigna

    Nilotinib

    arrow
    BioProcess International US West
    Not Confirmed

    Brand Name : Tasigna

    Switzerland
    arrow
    BioProcess International US West
    Not Confirmed

    Novartis

    Nilotinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 1,958

    2019 Revenue in Millions : 1,880

    Growth (%) : 4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Tasigna

    Nilotinib

    arrow
    BPI West
    Not Confirmed

    Brand Name : Tasigna

    Switzerland
    arrow
    BPI West
    Not Confirmed

    Novartis

    Nilotinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 2,060

    2020 Revenue in Millions : 1,958

    Growth (%) : 5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Tasigna

    Nilotinib

    arrow
    BPI West
    Not Confirmed

    Brand Name : Tasigna

    Switzerland
    arrow
    BPI West
    Not Confirmed

    Novartis

    Nilotinib

    Main Therapeutic Indication : Hematology

    Currency : USD

    2022 Revenue in Millions : 1,923

    2021 Revenue in Millions : 2,060

    Growth (%) : -7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Tasigna

    Nilotinib

    arrow
    BPI West
    Not Confirmed

    Brand Name : Tasigna

    Switzerland
    arrow
    BPI West
    Not Confirmed

    Novartis

    Nilotinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 1,848

    2022 Revenue in Millions : 1,923

    Growth (%) : -4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Tasigna

    Nilotinib

    arrow
    BPI West
    Not Confirmed

    Brand Name : Tasigna

    Switzerland
    arrow
    BPI West
    Not Confirmed

    Novartis

    Nilotinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2024 Revenue in Millions : 1,671

    2023 Revenue in Millions : 1,848

    Growth (%) : -10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Tasigna

    Nilotinib

    arrow
    BPI West
    Not Confirmed

    Brand Name : Tasigna

    Switzerland
    arrow
    BPI West
    Not Confirmed

    Novartis

    Nilotinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2014 Revenue in Millions : 20.80%

    2013 Revenue in Millions :

    Growth (%) :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Tasigna

    Nilotinib

    arrow
    BPI West
    Not Confirmed

    Brand Name : Tasigna

    Switzerland
    arrow
    BPI West
    Not Confirmed

    Novartis

    Nilotinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2015 Revenue in Millions : 1,529

    2014 Revenue in Millions : 1,632

    Growth (%) : 7%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Tasigna

    Nilotinib

    arrow
    BPI West
    Not Confirmed

    Brand Name : Tasigna

    Switzerland
    arrow
    BPI West
    Not Confirmed

    Novartis

    Nilotinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2016 Revenue in Millions : 1,739

    2015 Revenue in Millions : 1,632

    Growth (%) : 7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Tasigna

    Nilotinib

    arrow
    BioProcess International
    Not Confirmed

    Brand Name : Tasigna

    Switzerland
    arrow
    BioProcess International
    Not Confirmed

    Novartis

    Nilotinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2017 Revenue in Millions : 1,841

    2016 Revenue in Millions : 1,739

    Growth (%) : 6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Tasigna

    Nilotinib

    arrow
    BPI West
    Not Confirmed

    Brand Name : Tasigna

    Switzerland
    arrow
    BPI West
    Not Confirmed

    Novartis

    Nilotinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2018 Revenue in Millions : 1,874

    2017 Revenue in Millions : 1,841

    Growth (%) : 2%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.